Key result
Potassium binders such as patiromer and sodium zirconium cyclosilicate serve as maintenance therapy for hyperkalemia, allowing continuation of RAAS inhibitors despite potential GI symptoms.
Potassium binders like patiromer and sodium zirconium cyclosilicate can be used as maintenance therapy to manage hyperkalemia and enable continuation of RAAS inhibitors in high-risk patients.
In Brief Two medications that bind potassium in the gastrointestinal (GI) tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients. This strategy has an added advantage of allowing continuation of concomitant medications affecting the renin-angiotensin-aldosterone system. These medications are generally well tolerated but may cause GI symptoms and hypomagnesemia. Two medications that bind potassium in the gastrointestinal tract are indicated for hyperkalemia management. Patiromer and sodium zirconium cyclosilicate have been studied in patients with chronic kidney disease, diabetes, and heart failure. Recent studies have examined the role of potassium binders as maintenance therapy to control hyperkalemia in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Grace Earl (2020) conducted a review in Hyperkalemia. Potassium binders (Patiromer and sodium zirconium cyclosilicate) was evaluated. Potassium binders such as patiromer and sodium zirconium cyclosilicate serve as maintenance therapy for hyperkalemia, allowing continuation of RAAS inhibitors despite potential GI symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: